Strong killing activity towards specific ppCT peptide-loaded splenocytes, but not towards MART-126–35 peptide-loaded splenocytes used as a control, was seen 24 h after target cell administration, supporting the role of ppCT-specific CTLs in controlling tumour progression (Fig. 5b). This evidence concerns the gene SEPTIN4 and neoplasm.